Propanc Bio Stock Price, News & Analysis

Propanc Biopharma (PPCB) entered a strategic financing agreement with Hexstone Capital on Oct 15, 2025 for up to $100 million in potential funding.

Under the terms, Propanc will issue 100 shares of Series C Convertible Preferred Stock for an initial stated value of $10,000 each (initial investment $1 million). The Preferred is convertible at an initial price of $5.00 per share. The release describes that conversion price as a 280% premium in the headline and a 28% premium in the body versus a recent closing price of $1.78. Propanc also issued 9,900 warrants exercisable immediately to buy Preferred Stock at $9,999.99 each, representing up to $99 million of additional funding; warrants expire in 12 months. The agreement includes a 4.99% beneficial ownership limit and a company option to call up to 500 warrants per month at $0.01, enabling up to $5 million of Preferred issuance per month, subject to equity conditions. More details are in the company Form 8-K filed with the SEC.

Propanc (NASDAQ:PPCB) filed its annual 10-K for the year ended June 30, 2025 and reported major year‑end changes after an IPO and Nasdaq uplisting on August 14, 2025. Key reported items include total assets rising to $19.6 million (from ~ $72,000), stockholders' equity improving to $13.9 million (from a $3.8 million deficit), and a completed offering of 1,000,000 common shares generating $4.0 million gross. Management said development milestones for the lead therapeutic are anticipated by end of 2025 and through 2026, and the company intends to establish a $100 million or greater digital asset treasury within 12 months. The asset growth was attributed primarily to prepaid service contracts supporting market awareness, advisory, accounting, manufacturing, and R&D activities.

Propanc Biopharma (Nasdaq: PPCB) has received a certificate of grant from the USPTO for its "proenzyme composition" patent, marking its fourth US patent. The patent specifically covers a future clinical dose of PRP, the company's lead asset targeting metastatic cancer treatment.

The company's IP portfolio now includes 90 patents filed in major jurisdictions. PRP is targeting the global metastatic cancer treatment market, projected to reach $111.2 billion by 2027. The treatment works by inducing cell differentiation rather than directly killing cancer cells, offering a relatively non-toxic approach to treating metastatic cancer from solid tumors.

Propanc plans to commence a Phase 1B First-In-Human study next year and is pursuing capital raising initiatives, including a digital asset diversification strategy.

Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on cancer treatments, has announced plans to acquire $100 million worth of Ethereum over the next 12 months. This strategic move is part of a multi-faceted approach combining cryptocurrency exposure, pharmaceutical drug development, and asset acquisition.

The company aims to leverage Ethereum's advantages, including smart contracts, DApps capabilities, and its proof of stake mechanism. The strategy is designed to address cash flow needs during pre-revenue stage, diversify assets, and accelerate growth potential. Comparative data shows Ethereum's significant outperformance, with 5-year returns exceeding 1,000% compared to traditional indices like S&P 500 (86%) and Nasdaq (305%).

Propanc Biopharma (Nasdaq: PPCB) has provided a significant shareholder update following its successful IPO and Nasdaq uplisting. The company raised $4 million through an IPO of 1,000,000 shares at $4.00 per share, with trading commencing on August 15, 2025.

The company is preparing to advance its lead cancer treatment, PRP, into a Phase 1B First-In-Human study with 30-40 advanced cancer patients in 2026. PRP is a proenzyme mixture that acts as an EMT modulator, targeting various solid tumors. Additionally, Propanc is developing Rec-PRP, a synthetic backup compound, with pharmacology studies planned for Q1 2026.

The company has strengthened its leadership by appointing a new CFO and two Non-Executive Directors, and has raised $30 million since inception. The target market for PRP's initial indications (pancreatic and ovarian cancers) is projected to reach $18.1 billion by 2029.

Propanc Biopharma (NASDAQ: PPCB), a biopharmaceutical company focused on novel cancer treatments, has successfully completed its public offering and uplisting to the Nasdaq Capital Market. The company sold 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 Million.

Trading under the symbol "PPCB" commenced on August 15, 2025, with the offering closing on August 18, 2025. The underwriters, D. Boral Capital LLC and Craft Capital Management LLC, have a 45-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts.

Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on novel cancer treatments, has announced its uplisting to the Nasdaq Capital Market and pricing of a $4 million public offering. The company is offering 1,000,000 shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 150,000 shares.

Trading on Nasdaq is set to begin on August 15, 2025, transitioning from the OTC Markets Pink Tier. The offering, expected to close on August 18, 2025, will be managed by D. Boral Capital LLC and Craft Capital Management LLC. Proceeds will be used for working capital and general business purposes.

Propanc Biopharma (OTC Pink: PPCB) announced significant interest in their scientific publications on proenzymes cancer treatment. Two peer-reviewed articles reached 10 citations and 4,500 reads in August 2024. The first article, published in Scientific Reports, demonstrates the effectiveness of proenzymes in suppressing pancreatic Cancer Stem Cells. The second article highlights the anti-tumor efficacy of pancreatic proenzymes, particularly for pancreatic and ovarian cancers.

A clinical study led by Dr. Kenyon showed that 41.3% of late-stage cancer patients treated with proenzymes had significantly longer survival times than expected. With global market projections for pancreatic cancer drugs at $6.93 billion by 2030 and ovarian cancer drugs at $13.9 billion by 2029, Propanc Biopharma aims to advance its lead asset, PRP, into early-stage clinical development to address the pressing need for new therapies with fewer side effects.

Propanc Biopharma (OTC Pink: PPCB) has received a Notice of Allowance for its 'Proenzyme Composition' patent from the Canadian Intellectual Property Office. This patent broadly covers high dose and high ratio claims for future clinical doses of PRP, the company's lead asset for treating recurring and metastatic cancer. It's the second Canadian patent allowed or granted, part of Propanc's 93-patent portfolio filed in major jurisdictions. The patent is important for future clinical dosage ranges as Propanc advances towards a Phase 1 First-In-Human study in advanced cancer patients with solid tumors. PRP targets the global metastatic cancer treatment market, projected to reach $111.2 Billion by 2027. The patent has been granted in Europe, Japan, and South East Asia, and is under examination in the US.